MA30876B1 - Anticorps de la lymphotoxine-alpha - Google Patents

Anticorps de la lymphotoxine-alpha

Info

Publication number
MA30876B1
MA30876B1 MA31855A MA31855A MA30876B1 MA 30876 B1 MA30876 B1 MA 30876B1 MA 31855 A MA31855 A MA 31855A MA 31855 A MA31855 A MA 31855A MA 30876 B1 MA30876 B1 MA 30876B1
Authority
MA
Morocco
Prior art keywords
antibodies
lymphotoxin
alpha
chimeric
bind
Prior art date
Application number
MA31855A
Other languages
English (en)
Inventor
Camellia W Adams
Jane L Grogan
Austin L Gurney
Krista Mccutcheon
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA30876B1 publication Critical patent/MA30876B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00—Subject matter not provided for in other groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Business, Economics & Management (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Theoretical Computer Science (AREA)
  • General Business, Economics & Management (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)

Abstract

L'INVENTION PORTE SUR DIFFÉRENTS ANTICORPS QUI SE FIXENT À LA LYMPHOTOXINE-ALPHA, SUR LES MÉTHODES D'ÉLABORATION DE TELS ANTICORPS, SUR DES COMPOSITIONS ET ARTICLES INCORPORANT DE TELS ANTICORPS, ET SUR LEURS UTILISATIONS POUR LE TRAITEMENT, PAR EXEMPLE, DE TROUBLES AUTOIMMUNES. LESDITS ANTICORPS COMPRENNENT DES ANTICORPS MURINS, CHIMÈRES ET HUMANISÉS.
MA31855A 2006-10-12 2009-05-08 Anticorps de la lymphotoxine-alpha MA30876B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82925706P 2006-10-12 2006-10-12
US93899907P 2007-05-18 2007-05-18

Publications (1)

Publication Number Publication Date
MA30876B1 true MA30876B1 (fr) 2009-11-02

Family

ID=39430415

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31855A MA30876B1 (fr) 2006-10-12 2009-05-08 Anticorps de la lymphotoxine-alpha

Country Status (21)

Country Link
US (4) US7923011B2 (fr)
EP (1) EP2084188A2 (fr)
JP (1) JP5298021B2 (fr)
KR (1) KR20090078349A (fr)
AR (1) AR063257A1 (fr)
AU (1) AU2007324135B2 (fr)
BR (1) BRPI0715580A2 (fr)
CA (1) CA2665644A1 (fr)
CL (1) CL2007002926A1 (fr)
CO (1) CO6220841A2 (fr)
CR (1) CR10705A (fr)
IL (1) IL197937A0 (fr)
MA (1) MA30876B1 (fr)
MX (1) MX2009003774A (fr)
NO (1) NO20091841L (fr)
NZ (1) NZ576032A (fr)
PE (1) PE20080980A1 (fr)
RU (1) RU2486201C2 (fr)
TW (1) TWI414531B (fr)
UA (1) UA94484C2 (fr)
WO (1) WO2008063776A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102216452B (zh) * 2008-09-26 2013-08-21 尤里卡治疗公司 具有变异糖基化方式的细胞系和蛋白质
BRPI0913687A2 (pt) * 2008-09-30 2015-10-13 Genentech Inc marcadores biológicos preditivos da resposta da artrite reumatóide aos antagonistas da linfotoxina
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011060015A1 (fr) 2009-11-11 2011-05-19 Genentech, Inc. Procédés et compositions de détection de protéines cibles
RU2012147249A (ru) * 2010-04-07 2014-05-20 Эббви Инк. TNF-α- СВЯЗЫВАЮЩИЕ БЕЛКИ
CN103025354A (zh) 2010-06-02 2013-04-03 大日本住友制药株式会社 自身免疫疾病和变应性疾病的治疗药
CN102621310B (zh) * 2011-01-28 2014-07-02 上海科新生物技术股份有限公司 胶体金层析法抗u1-rnp抗体检测试纸及其制备方法
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
WO2013114164A1 (fr) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Procédé d'obtention d'une composition glycoprotéique ayant une concentration accrue d'afucosylation
KR102293061B1 (ko) 2012-05-21 2021-08-23 제넨테크, 인크. 혈액-뇌 장벽 수송의 안전성을 개선하는 방법
GB201314052D0 (en) 2013-08-06 2013-09-18 Apitope Int Nv Peptides
EP2935611B1 (fr) * 2013-10-14 2021-07-07 SynAffix B.V. Anticorps obtenu par glyco-ingénierie, conjugué d'anticorps, et procédés pour leur préparation
WO2015057906A1 (fr) * 2013-10-16 2015-04-23 Janssen Biotech, Inc. Agonistes 1 du récepteur cd200
KR101820572B1 (ko) * 2015-08-12 2018-01-19 가톨릭대학교 산학협력단 만성골수성백혈병에 관한 정보 제공 방법
EP3925970A1 (fr) 2015-11-02 2021-12-22 F. Hoffmann-La Roche AG Procédés de fabrication de formes fucosylées et afucosylées d'une protéine
US12054558B2 (en) 2018-05-23 2024-08-06 The Jackson Laboratory Anti-NGly-1 antibodies and methods of use
WO2020099119A1 (fr) * 2018-11-16 2020-05-22 Consejo Superior De Investigaciones Cientificas Variants d'étanercept ayant un effet thérapeutique amélioré
CN111285936A (zh) * 2020-03-11 2020-06-16 北京双赢科创生物科技有限公司 靶向肿瘤的酸性敏感纳米肽段及其应用

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4920196A (en) 1982-07-30 1990-04-24 Genentech, Inc. Human lymphotoxin
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
IL75318A (en) * 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production
US4959457A (en) 1984-05-31 1990-09-25 Genentech, Inc. Anti-lymphotoxin
US5683688A (en) 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
DE3850542T2 (de) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
JPH023698A (ja) 1988-06-20 1990-01-09 Denki Kagaku Kogyo Kk ヒトリンホトキシンに対するモノクローナル抗体及びそれら抗体を産生するハイブリドーマ、並びにそれら抗体を用いたヒトリンホトキシンの精製方法、測定方法及び測定試薬
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6475787B1 (en) 1989-07-28 2002-11-05 Wyeth Method for producing monoclonal antibodies
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US7030080B2 (en) 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
ES2157889T3 (es) 1990-06-27 2001-09-01 Biogen Inc Linfotoxina complejada de superficie.
US5670149A (en) 1990-06-27 1997-09-23 Biogen, Inc. Lymphotoxin-β, Lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0814159B1 (fr) 1990-08-29 2005-07-27 GenPharm International, Inc. Souris transgéniques capables de produire des anticorps hétérologues
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
JP3672306B2 (ja) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
RU2048521C1 (ru) * 1992-05-25 1995-11-20 Научно-Исследовательский Конструкторско-Технологический Институт Биологически Активных Веществ Способ получения полипептида со свойствами лимфотоксина человека
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US20050255104A1 (en) 1993-01-29 2005-11-17 Centocor, Inc. Methods of treating psoriasis using anti-TNF receptor fusion proteins
US5747023A (en) 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US5747373A (en) * 1996-09-24 1998-05-05 Taiwan Semiconductor Manufacturing Company Ltd. Nitride-oxide sidewall spacer for salicide formation
US7255854B1 (en) 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
KR100584704B1 (ko) 1996-10-25 2006-05-30 바이오겐 아이덱 엠에이 인코포레이티드 면역 질환을 치료하기 위한 치료제로서의 가용성 림포톡신-베타 수용체, 항림포톡신 수용체 항체 및 항림포톡신 리간드 항체
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
ES2340112T3 (es) 1998-04-20 2010-05-28 Glycart Biotechnology Ag Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
AU4930399A (en) 1998-07-29 2000-02-21 Kyowa Hakko Kogyo Co. Ltd. Novel Polypeptide
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
PL209786B1 (pl) * 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ATE488250T1 (de) 1999-03-02 2010-12-15 Centocor Inc Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma
CA2704600C (fr) 1999-04-09 2016-10-25 Kyowa Hakko Kirin Co., Ltd. Methode de production d'anticorps avec activite adcc accrue
JP4668498B2 (ja) 1999-10-19 2011-04-13 協和発酵キリン株式会社 ポリペプチドの製造方法
US7056695B2 (en) 2000-03-02 2006-06-06 Xencor TNF-α variants
KR20020093029A (ko) 2000-04-11 2002-12-12 제넨테크, 인크. 다가 항체 및 그의 용도
WO2002002641A1 (fr) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b
US20060034828A1 (en) 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
EP1297172B1 (fr) 2000-06-28 2005-11-09 Glycofi, Inc. Procede de production de glycoproteines modifiees
US20060034830A1 (en) 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US20060029604A1 (en) * 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CA2425809A1 (fr) 2000-10-13 2002-04-18 Biogen, Inc. Anticorps humanises anti-lt-.beta.-r
CA2433353C (fr) 2000-12-28 2017-03-21 Altus Biologics, Inc. Cristaux d'anticorps entiers et fragments d'anticorps et methodes de fabrication et d'utilisation associees
US20050271663A1 (en) 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2002363354A1 (en) 2001-07-27 2003-05-19 Human Genome Sciences, Inc. Heteromultimeric tnf ligand family members
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
MXPA04003798A (es) 2001-10-25 2004-07-30 Genentech Inc Composiciones de glicoproteina.
EP1585477A4 (fr) 2001-11-30 2007-06-27 Centocor Inc Anticorps anti-tnf, compositions, procedes et utilisations
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003215130A1 (en) 2002-02-08 2003-09-02 Wyeth Composition and method for modulating an inflammatory response
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
JP4832719B2 (ja) 2002-04-09 2011-12-07 協和発酵キリン株式会社 ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬
AU2003236015A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition
JPWO2003084569A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物含有医薬
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
EP1499353A4 (fr) 2002-04-15 2006-04-05 Human Genome Sciences Inc Anticorps se liant specifiquement au tl5
EP1539793A4 (fr) 2002-07-01 2006-02-01 Anticorps humanises diriges contre le recepteur de la lymphotoxine beta
US6873910B2 (en) * 2002-10-22 2005-03-29 Qualcomm Incorporated Procedure for searching for position determination signals using a plurality of search modes
AU2003287431A1 (en) 2002-10-31 2004-05-25 Biogen Idec Ma Inc. Treatment of immunological renal disorders by lymphotoxin pathway inhibitors
BRPI0316779B1 (pt) 2002-12-16 2020-04-28 Genentech Inc anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
PL377611A1 (pl) 2002-12-20 2006-02-06 Biogen Idec Ma Inc. Czynniki dla receptora limfotoksyny beta w połączeniu z czynnikami chemioterapeutycznymi
ES2335005T5 (es) 2003-03-05 2013-04-17 Halozyme, Inc. Glicoproteína hialuronidasa soluble (shasegp), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
WO2005018572A2 (fr) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Anticorps ameliores possedant une fonction d'effecteur modifiee et procedes de fabrication associes
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
CA2542125A1 (fr) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Procede permettant de produire une composition d'anticorps par inhibition par l'arn de la fonction de .alpha.1,6-fucosyltransferase
SI2380911T1 (en) 2003-11-05 2018-07-31 Roche Glycart Ag ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION
KR100772800B1 (ko) 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
WO2005053742A1 (fr) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition a base d'anticorps
US20050266004A1 (en) * 2003-12-08 2005-12-01 Jill Giles-Komar Anti-human lymphotoxin alpha antibodies, compositions, methods and uses
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
CA2573541A1 (fr) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulines comprenant principalement une glycoforme de type man<sb>3</sb>glcnac<sb>2</sb>
JP2008507535A (ja) 2004-07-21 2008-03-13 グライコフィ， インコーポレイテッド 主にｍａｎ５ｇｌｃｎａｃ２グリコフォームを含むイムノグロブリン
AU2005269763A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a Gal2GlcNac2Man3GlcNac2 glycoform
CA2573864A1 (fr) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulines comprenant principalement une glycoforme glcnacman<sb>5</sb>glcnac<sb>2</sb>
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
AU2005285347A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
JP2006228261A (ja) 2005-02-15 2006-08-31 Micron Technology Inc デジット線絶縁ゲートの負電圧駆動
CA2605781A1 (fr) 2005-05-09 2007-04-12 Glycart Biotechnology Ag Molecules de liaison a l'antigene possedant des zones fc modifiees et une liaison alteree aux recepteurs fc

Also Published As

Publication number Publication date
CL2007002926A1 (es) 2008-05-16
US8216807B2 (en) 2012-07-10
EP2084188A2 (fr) 2009-08-05
US20090285830A1 (en) 2009-11-19
US20130011412A1 (en) 2013-01-10
CR10705A (es) 2009-05-07
RU2009117680A (ru) 2010-11-20
JP5298021B2 (ja) 2013-09-25
CO6220841A2 (es) 2010-11-19
AU2007324135A1 (en) 2008-05-29
US20110208673A1 (en) 2011-08-25
US8541552B2 (en) 2013-09-24
KR20090078349A (ko) 2009-07-17
BRPI0715580A2 (pt) 2014-06-10
IL197937A0 (en) 2011-08-01
TW200825101A (en) 2008-06-16
NO20091841L (no) 2009-07-13
TWI414531B (zh) 2013-11-11
AU2007324135B2 (en) 2013-06-27
WO2008063776A3 (fr) 2009-03-05
JP2010506568A (ja) 2010-03-04
UA94484C2 (uk) 2011-05-10
WO2008063776A2 (fr) 2008-05-29
US20110150865A1 (en) 2011-06-23
CA2665644A1 (fr) 2008-05-29
MX2009003774A (es) 2009-04-22
NZ576032A (en) 2012-03-30
RU2486201C2 (ru) 2013-06-27
PE20080980A1 (es) 2008-09-02
AR063257A1 (es) 2009-01-14
US7923011B2 (en) 2011-04-12
US8642740B2 (en) 2014-02-04

Similar Documents

Publication Publication Date Title
MA30876B1 (fr) Anticorps de la lymphotoxine-alpha
LUC00053I9 (fr) Anticorps diriges contre cd38 pour le traitement du myelome multiple
BR0211953A (pt) Inibidores de rota complementar ligando-se a cs e csa sem prevenção da formação de csb
MA33285B1 (fr) Anticorps anti-cxcr4 pour le traitement du vih
MA40041A (fr) Anticorps anti-gitr et leurs procédés d&#39;utilisation
MA44312A (fr) Anticorps et leurs méthodes d&#39;utilisation
GEP20104922B (en) Antibodies to m-csf
TNSN07398A1 (fr) Anticorps contre la p-cadherine
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d&#39;utilisation
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
MA33052B1 (fr) Variants de liaison anti-albumine sérique améliorés
TW200709817A (en) Platform antibody compositions
NZ599628A (en) Axl antibodies
MX2007000023A (es) Anticuerpos del receptor uno de interferon alfa, y sus usos.
MA34813B1 (fr) Utilisation de lymphocytes t modifies par un recepteur chimerique d&#39;antigenes chimerique pour traiter le cancer
MA30337B1 (fr) Anticorps
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
MY151191A (en) Novel antibodies
TW200603828A (en) Treatment of disorders
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo
MA38161A1 (fr) Anticorps anti-bmp-6
ATE423100T1 (de) Neue chinolinverbindungen, die dazu in der lage sind, sich an den cb2-rezeptor zu binden